New Drugs 2019, part 1Nursing2019: February 2019 - Volume 49 - Issue 2 - p 36–37 doi: 10.1097/01.NURSE.0000553312.06244.76 CE Connection Free Author InformationAuthors Article OutlineOutline Article MetricsMetrics For more than 79 additional continuing-education articles related to pharmacology topics, go to NursingCenter.com/CE. Earn CE credit online: Go to www.nursingcenter.com/CE/nursing and receive a certificate within minutes. Nursing2019 will no longer facilitate mail-in continuing-education tests. All CE tests must be taken online at www.nursingcenter.com/ce/nursing. Please address any questions to customer service at 1-800-787-8985. INSTRUCTIONS New Drugs 2019, part 1 TEST INSTRUCTIONS PROVIDER ACCREDITATION Back to Top | Article Outline INSTRUCTIONS New Drugs 2019, part 1 TEST INSTRUCTIONS Read the article. The test for this CE activity is to be taken online at www.nursingcenter.com/CE/nursing. You'll need to create (it's free!) and log in to your personal CE Planner account before taking online tests. Your planner will keep track of all your Lippincott Professional Development online CE activities for you. There's only one correct answer for each question. A passing score for this test is 13 correct answers. If you pass, you can print your certificate of earned contact hours and access the answer key. If you fail, you have the option of taking the test again at no additional cost. For questions, contact Lippincott Professional Development: 1-800-787-8985. Registration deadline is December 4, 2020. Back to Top | Article Outline PROVIDER ACCREDITATION Lippincott Professional Development will award 1.5 contact hours and 1.5 pharmacology credits for this continuing nursing education activity. Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 1.5 contact hours, and the District of Columbia, Georgia, and Florida CE Broker #50-1223. Payment: The registration fee for this test is $17.95. New Drugs 2019, part 1 GENERAL PURPOSE: To present information about seven drugs recently approved by the FDA. LEARNING OBJECTIVES/OUTCOMES: After completing this continuing-education activity, you should be able to: 1. Describe indications for seven newly approved drugs. 2. Identify nursing implications for these new drugs. How often should patients self-administer semaglutide? once a day twice a day once a week Teach patients who are beginning therapy with semaglutide to administer the medication immediately before a meal. administer the medication before bedtime. store the medication in a refrigerator before first use. The labeling for ertugliflozin contains a warning about the risk of permanent vision loss. lower limb amputation. myocardial infarction. Nurses should instruct patients to take each dose of ertugliflozin in the morning without regard to food. before breakfast. after breakfast. Nurses should instruct patients to report which of the following adverse reactions to ertugliflozin? nausea dysuria headache Benralizumab is administered orally. via inhalation. via subcutaneous injection. A possible adverse reaction to benralizumab is pharyngitis. arthralgia. tinnitus. Initially, benralizumab is administered once every week. 2 weeks. 4 weeks. Tezacaftor/ivacaftor is a combination medication indicated to treat asthma. cystic fibrosis. retinal dystrophy. Patients being treated with tezacaftor/ivacaftor should take the yellow tablet in the evening. blue tablet in the morning. blue tablet in the evening. Nurses could suggest that patients taking tezacaftor/ivacaftor take each dose with a whole-milk dairy product. orange juice. grapefruit juice. For treating impetigo, ozenoxacin is available in which of the following formulations? cream lotion ointment Nurses should instruct parents or their caregivers to apply ozenoxacin to the affected area once a day for 7 days. twice a day for 5 days. three times a day for 10 days. Possible adverse reactions to netarsudil include macular holes. corneal opacities. subretinal deposits. Instruct patients using other ophthalmic medications concurrently with netarsudil to administer them at least how many minutes apart? 5 10 15 Netarsudil is classified as a(n) SGLT2 inhibitor. Rho kinase inhibitor. CFTR potentiator. Adverse reactions to voretigene include cataracts. uveitis. scleral discoloration. Immediately after voretigene administration, patients should remain in a semi-Fowler position. prone. supine. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.